Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Saved in:
| Title: | Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
|---|---|
| Authors: | van Asselt, Antoinette D. I.1,2 (AUTHOR) a.d.i.van.asselt@umcg.nl, Armstrong, Nigel3 (AUTHOR), Kimman, Merel4,5 (AUTHOR), Peeters, Andrea4 (AUTHOR), McDermott, Kevin3 (AUTHOR), Stirk, Lisa3 (AUTHOR), Ahmadu, Charlotte3 (AUTHOR), Govers, Tim M.6 (AUTHOR), Hoentjen, Frank7,8 (AUTHOR), Joore, Manuela A.4,5 (AUTHOR), Grimm, Sabine E.4 (AUTHOR) |
| Source: | PharmacoEconomics. Mar2023, Vol. 41 Issue 3, p239-251. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
